Your browser doesn't support javascript.
loading
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy.
McDonald, Craig M; Meier, Thomas; Voit, Thomas; Schara, Ulrike; Straathof, Chiara S M; D'Angelo, M Grazia; Bernert, Günther; Cuisset, Jean-Marie; Finkel, Richard S; Goemans, Nathalie; Rummey, Christian; Leinonen, Mika; Spagnolo, Paolo; Buyse, Gunnar M.
Afiliación
  • McDonald CM; University of California Davis Medical Center, Sacramento, CA, USA.
  • Meier T; Santhera Pharmaceuticals, Liestal, Switzerland.
  • Voit T; Institut de Myologie, UPMC INSERM UMR 974, CNRS FRE 3617, Groupe Hospitalier de la Pitié Salpêtrière, Paris, France.
  • Schara U; Universitätsklinikum, Essen, Germany.
  • Straathof CS; LUMC, Leiden, The Netherlands.
  • D'Angelo MG; IRCCS Eugenio Medea, Lecco, Italy.
  • Bernert G; G.v. Preyer'sches Kinderspital, Wien, Austria.
  • Cuisset JM; CHRU de Lille, Lille, France.
  • Finkel RS; Nemours Children's Hospital, Orlando, FL, USA.
  • Goemans N; University Hospitals Leuven, Leuven, Belgium.
  • Rummey C; 4Pharma, Liestal, Switzerland.
  • Leinonen M; 4Pharma, Liestal, Switzerland.
  • Spagnolo P; Santhera Pharmaceuticals, Liestal, Switzerland.
  • Buyse GM; University Hospitals Leuven, Leuven, Belgium. Electronic address: gunnar.buyse@uzleuven.be.
Neuromuscul Disord ; 26(8): 473-80, 2016 08.
Article en En | MEDLINE | ID: mdl-27238057
In Duchenne muscular dystrophy (DMD), progressive loss of respiratory function leads to restrictive pulmonary disease and places patients at significant risk for severe respiratory complications. Of particular concern are ineffective cough, secretion retention and recurrent respiratory tract infections. In a Phase 3 randomized controlled study (DMD Long-term Idebenone Study, DELOS) in DMD patients 10-18 years of age and not taking concomitant glucocorticoid steroids, idebenone (900 mg/day) reduced significantly the loss of respiratory function over a 1-year study period. In a post-hoc analysis of DELOS we found that more patients in the placebo group compared to the idebenone group experienced bronchopulmonary adverse events (BAEs): placebo: 17 of 33 patients, 28 events; idebenone: 6 of 31 patients, 7 events. The hazard ratios (HR) calculated "by patient" (HR 0.33, p = 0.0187) and for "all BAEs" (HR 0.28, p = 0.0026) indicated a clear idebenone treatment effect. The overall duration of BAEs was 222 days (placebo) vs. 82 days (idebenone). In addition, there was also a difference in the use of systemic antibiotics utilized for the treatment of BAEs. In the placebo group, 13 patients (39.4%) reported 17 episodes of antibiotic use compared to 7 patients (22.6%) reporting 8 episodes of antibiotic use in the idebenone group. Furthermore, patients in the placebo group used systemic antibiotics for longer (105 days) compared to patients in the idebenone group (65 days). This post-hoc analysis of DELOS indicates that the protective effect of idebenone on respiratory function is associated with a reduced risk of bronchopulmonary complications and a reduced need for systemic antibiotics.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Respiratorias / Ubiquinona / Distrofia Muscular de Duchenne / Antioxidantes Tipo de estudio: Clinical_trials / Incidence_studies / Prognostic_studies Límite: Adolescent / Child / Humans Idioma: En Revista: Neuromuscul Disord Asunto de la revista: NEUROLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Respiratorias / Ubiquinona / Distrofia Muscular de Duchenne / Antioxidantes Tipo de estudio: Clinical_trials / Incidence_studies / Prognostic_studies Límite: Adolescent / Child / Humans Idioma: En Revista: Neuromuscul Disord Asunto de la revista: NEUROLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido